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Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that are
implicated in the regulation of lipid and glucose homeostasis. PPAR agonists have been shown to control
inflammatory processes, in part by inhibiting the expression of distinct proinflammatory genes such as vascular cell
adhesion molecule-1 (VCAM-1), IL-8, and intercellular adhesion molecule-1 (ICAM-1). ICAM-1 is an important
endothelial membrane receptor that facilitates the transmigration of leukocytes across the endothelium. To date,
the influence of PPARα and δ activators on the expression of ICAM-1 in non-induced, quiescent endothelial cells
has been unclear. Therefore, we examined the effects of various PPARα and δ agonists on the expression of ICAM-1
in non-stimulated primary human endothelial cells.
Results: We found that PPARα and PPARδ agonists significantly induced ICAM-1 surface, intracellular protein, and
mRNA expression in a time and concentration-dependent manner. The PPARδ induced ICAM-1 expression could be
paralleled with a significantly increased T-cell adherence to the endothelial cells whereas PPARα failed to do so.
Transcriptional activity studies using an ICAM-1 reporter gene constructs revealed that PPARδ, but not PPARα
agonists induced gene expression by stimulating ICAM-1 promoter activity via an Sp1 transcription factor binding
site and inhibit the binding of the transcription factors Sp1 and Sp3. Furthermore, we performed mRNA stability
assays and found that PPARα and PPARδ agonists increased ICAM-1 mRNA stability.
Conclusion: Therefore, our data provide the first evidence that PPARα and PPARδ agonists induce ICAM-1
expression in non-stimulated endothelial cells via transcriptional and posttranscriptional mechanisms.
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Background
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor-activated transcription
factor superfamily comprised of three subtypes: PPARα,
PPARδ, and PPARγ. The role of PPARs was originally
thought to be restricted to lipid metabolism, glucose
homeostasis, and cellular differentiation [1–4]. PPARs
can be activated by natural ligands such as eicosanoids or
fatty acids. In addition, synthetic antidiabetic thiazolidine-
diones and lipid-lowering fibrates have been shown to act
as activators of PPARγ and PPARα, respectively [5–7].
Recent evidence suggests that PPARδ plays a crucial role
in the regulation of differentiation, cell growth, and the
metabolism of lipids and glucose [8–11]. Previous studies
demonstrated that PPARδ agonists improve insulin
sensitivity and therefore might be interesting targets for
the treatment of obesity-associated disorders [12–14].
In the last few years, several studies have revealed the
impact of PPARα and PPARδ on endothelial cell function.
During inflammation, proinflammatory stimuli, including
LPS, TNFα or IL-1β, cause phenotypic changes to the
quiescent endothelium by inducing the expression of proin-
flammatory factors such as IL-6 and IL-8 or adhesion
molecules such as ICAM-1 and VCAM-1. Fan et al. dem-
onstrated that the PPARδ agonist GW501516 suppressed
IL-1β-induced VCAM-1 and E-selectin expression in
human umbilical vein endothelial cells (HUVECs) [15].
Furthermore, Rival et al. showed that the PPARδ activator
L-165041 suppressed TNFα-induced VCAM-1 and MCP-1
expression [16]. Huang et al. revealed that ICAM-1 expres-
sion could be attenuated by PPARα activation via fenofi-
brate in TNFα - activated human aortic endothelial cells
[17]. Piqueras demonstrated, that TNFα induced ICAM-1
expression in endothelial cells can be partly suppressed by
PPARδ agonists [18]. Taken together, these studies demon-
strate that PPARα/δ agonists play a role in suppressing the
proinflammatory response in stimulated endothelial cells.
On the other hand, there is also evidence that PPAR
agonists have proinflammatory properties in non-
inflammatory, quiescent endothelial cells. Chen et al.
demonstrated that PPARγ agonists significantly induced
ICAM-1 expression in human endothelial cells [19]. In
addition, PPARδ agonists were shown to induce IL-6
and IL-8 expression in non-stimulated human endothe-
lial cells via increased induction and translocation of
NfkB [20]. Recently, Gu et al. demonstrated, that the
PPARα agonists fenofibrate induces inflammation in
experimental acute colitis mice [21]. Furthermore, Wang
et al. demonstrated that PPARδ promotes colonic
inflammation and colitis-associated tumor growth via
the COX-2-derived PGE2 signaling [22]. Therefore, it is
important, that not only the anti-inflammatory action of
PPARs but also the possible pro-inflammatory properties
are investigated.
The impact of PPARα and PPARδ agonists on ICAM-
1 expression in quiescent non stimulated endothelial
cells has yet to be assessed. Understanding the conse-
quences of PPAR signaling is of importance due to the
possible wide range use of PPAR agonists in various
diseases such as chronic inflammation, glucose metabol-
ism, dyslipidemia, obesity, cancer therapy, and poten-
tially many more. In the present study, we analyzed the
effects of PPARα and PPARδ activators on the expres-
sion of ICAM-1 in non-stimulated HUVECs. Further-
more, we investigated the mechanisms by which PPAR
agonists exert their influence within these cells.
Methods
Reagents
Recombinant human TNFα was purchased from R&D
Systems (Minneapolis, MN, USA). L-165041, GW501546,
WY14643, Fenofibrate and Actinomycin-D were obtained
from Sigma-Aldrich (Hamburg, Germany).
Cell culture
HUVECs were purchased from PromoCell (Heidelberg,
Germany) and were cultured until the fifth passage at
37 °C and 5 % CO2 in Endothelial Cell Growth Medium
(Cambrex, East Rutherford, NJ, USA). Jurkat cells were
obtained from ATCC (LGC Standards; Wesel, Germany)
and cultured at 37 °C and 5 % CO2 atmosphere in
RPMI-1640 medium supplemented with 10 % fetal
bovine serum (FBS) and 2 mM glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin.
Fluorescence-activated cell sorting analysis
HUVECs were treated with PPARα and PPARδ agonists
for 24 h. The treated cells were incubated with mouse
anti-human ICAM-1 fluorescein-conjugated mAb (Clone
#BBIG-1; 1:200 dilution; R&D Systems, Wiesbaden,
Germany) or isotype control mouse anti-human IgG1
(R&D Systems, Wiesbaden, Germany) for 30 min on ice.
Isotype control cells were then incubated with
fluorescein-conjugated affinity-purified goat F(ab´)2 anti-
mouse IgG (F0479; DAKO, Hamburg, Germany) at a
1:100 dilution for 30 min, and cells were subsequently an-
alyzed by a BD FACScan Cytometer (Becton–Dickinson,
Franklin Lakes, NJ, USA). Nonviable cells were identified
and excluded by propidium iodide staining.
Western blot analysis
Whole cell protein was prepared as previously described
[23]. Membranes were incubated with the indicated
primary antibodies. Antibodies were as follows: anti-
ICAM-1 (SC-107; 15.2) from Santa Cruz (Heidelberg,
Germany) and anti-Tubulinα Ab-2 (DM1A) from LabVi-
sion (Fremont, CA, USA). Primary antibody application
was followed by incubation with horseradish peroxidase-
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conjugated secondary antibodies (anti-mouse and anti-
rabbit IgG, Amersham, Uppsala, Sweden; anti-goat, Dako,
Glostrup, Denmark). Blots were developed using an en-
hanced chemiluminescence detection system (ECL)
(Amersham, Uppsala, Sweden), according to the manufac-
turer’s instructions. Densitometry was used to quantify
band intensities using ImageJ (v1.29 s). Optical densities
of the bands were corrected for loading differences based
on corresponding control bands.
Flow chamber assays
Adhesion was determined using Ibidi μ-slide VI cham-
bers (Munich, Germany) [24]. Two days before treat-
ment 1,8x105 HUVECs were seeded in each chamber.
The day before treatment HUVECs were serum-starved
(0,5 % FBS) for 24 h. After 24 h the HUVECs were
treated with PPARδ or PPARα agonists (L-165,041
(50 μM); GW501516 (20 μM); Fenofibrate (100 μM);
WY14643 (200 μM)) or TNFα (20 ng/ml) for 6 h. 5x104
Jurkat cells were allowed to attach on the endothelium
for 3 min. Non-adherent cells were flushed away and
shear stress was increased stepwise from 0.35 to 2, 5, 8
and 15 dyn/cm2 for 30 s each. Every 30 s the number of
adherent cells was quantified, with a charge-coupled
device (CCD) camera (Sony, New Jersey, USA).
RNA extraction and RT-PCR
RT-PCR analyses were performed using total RNA
(150 ng) extracted from sub-confluent cell cultures.
Total cellular mRNA was isolated by the RNeasy Mini
Procedure (Qiagen, Hilden, Germany) after DNase
digestion. RT-PCR analyses for ICAM-1 and GAPDH
were performed using the One Step RT-PCR Kit
(Qiagen). PCR products were resolved by 1–2 % agarose
gel electrophoresis, and ethidium bromide-stained bands
were visualized with an ultraviolet transilluminator. The
primer sets for ICAM-1 and GAPDH have been
previously published [23]. Densitometry was used to
quantify band intensities using ImageJ (v1.29 s). Optical
densities of the bands were corrected for loading
differences based on corresponding control bands.
Transient transfection and analysis of reporter gene
expression
HUVECs (1.0 × 105 cells/well in 12-well plates) were
transfected with 0.5 μg of the appropriate firefly luciferase
construct and 0.1 μg phRG-TK vector (Promega, Madison,
WI, USA) using the SuperFect transfection reagent
(Qiagen). Human ICAM-1 full length reporter gene con-
struct -1014 pIC was generously provided by Paul van der
Saag, Hubrecht Laboratorium, Utrecht, The Netherlands
and sublconed in a pGL3 luciferase vector (Promega,
Madison, WI, USA) [25]. In addition, four new deletional
ICAM-1 promoter constructs containing 5′regulatory
elements were established in the pGL3 luciferase vector
using PCR amplification (HotStar HiFidility Polymerase
Kit; Qiagen) and KpnI and BglII restriction sites. The
−1014 gene construct was used as a template. All
constructs were sequenced from the 5′- and 3′-ends to
confirm orientation and sequence correctness. Twenty-
four hours after transfection, cells were treated with
vehicle (DMSO, 0.3 %) or the appropiate PPAR agonist for
24 h. Luciferase activities were measured with the Dual-
Luciferase Reporter Assay System (Promega).
Preparation of nuclear extracts and electrophoretic
mobility shift assay (EMSA)
HUVECs were treated with vehicle (0.1 % DMSO) or
L-165041 for 30 min. Nuclear proteins were extracted as
described previously [26]. An ICAM-1 promoter specific
oligonucleotide between −69 and −45 bp containing the
Sp1 site between −53 and −59 bp was constructed (5′-
primer: GAAAGCAGCACCGCCCCTTGGCCC (Sp1-site
in bold letters); 3′primer: GGGCCAAGG). In addition, a
Sp1 mutated olignucleotoide was constructed carrying two
nucleotide mutations within the Sp1 consensus sequence
(5′primer: GAAAGCAGCACAGACCCTTGGCCC (mu-
tated Sp1-site in bold letters, exchanged nucleotides in
italic); 3′primer: GGGCCAAGG). DNA-binding reactions
were performed with or without excess unlabeled competi-
tor, Sp1 consensus-oligonucleotide (Promega), wildtype Sp1
oligo and mutated Sp1 oligo as well as Sp1 and Sp3
antibodies (SC-59 (PEP2); SC644 (D-20)Santa Cruz
Biotechnology, Santa Cruz, CA).
Statistical analyses
The data are expressed as means ± SEM from at least
three independent experiments. Statistical analyses were
performed using the ANOVA test.
Results
PPARα and δ agonists induce ICAM-1 surface and whole
cell protein expression in non-stimulated human
endothelial cells
We performed FACS analysis to evaluate the effects of
the PPARα agonists fenofibrate and WY14643 as well as
the PPARδ agonists L165041 and GW501516 on the
surface expression of ICAM-1 in non-stimulated, quies-
cent HUVECS. The concentrations of the PPAR agonists
were used as published and do not induce any cytotox-
icity as previously shown [12, 20, 26–29]. Treatment of
non-stimulated HUVECs with each agonist resulted in
an induction of ICAM-1 surface expression (Fig. 1a).
The level of induction was comparable between the two
agonists of each PPAR, indicating that the observed
effects are specific to PPARα and PPARδ. We also exam-
ined the effects of PPARα and PPARδ agonists on whole
cell protein expression of ICAM-1. Western blot analysis
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of whole-cell extracts demonstrated that both PPAR
agonists induced ICAM-1 expression in a concentration
and time-dependent manner (Fig. 1b,c). To analyze
whether the general ICAM-1 induction on endothelial
cells has a functional consequence, we performed
adhesion assays with the T-cell line Jurkat and PPARδ
and PPARα agonists treated HUVEC as a proof of
concept (Fig. 1d,e). Here we could demonstrate, that the
PPARδ agonist induced ICAM-1 expression elevates the
adherence of Jurkat cells significantly whereas PPARα
agonists failed to increase T-cell adherence.
PPARα and δ agonists induce ICAM-1 steady-state mRNA
expression
We examined whether PPARα and PPARδ agonists affect
the steady-state mRNA levels of ICAM-1 in HUVECs.
Consistent with our protein expression data, treatment with
both PPARα and PPARδ agonists induced ICAM-1 mRNA
expression in a concentration-dependent manner (Fig. 2).
PPARδ, but not PPARα agonists upregulate ICAM-1
promoter activity via a Sp1 binding site between −59
and −53 bp
We hypothesized that PPARα and PPARδ agonists induce
ICAM-1 expression through transcriptional regulation of
the ICAM-1 promoter. To test this possibility, a luciferase
reporter construct containing all transcription factor bind-
ing sites of the ICAM-1 promoter was transiently trans-
fected into vehicle- and agonist-treated HUVECs. Analysis
of luciferase expression revealed a significant 1,4-fold
induction of ICAM-1 promoter activity in response to
PPARδ agonist. However, PPARα agonist treatment failed
(See figure on previous page.)
Fig. 1 Effects of PPARα and δ agonists on the ICAM-1 surface and protein expression as well as funtion in non-stimulated HUVEC. a Flow-cytometric
analyses of ICAM-1 expression; HUVECs were left untreated (solvent only) or were treated with different concentrations of PPARα agonsist (WY14643 (100
and 200 μM) and Fenofibrate (100 and 200 μM) or PPARδ agonists (L-165041 (25 and 50 μM) and GW501514 (10 and 20 μM)). As positive control TNFα
(20 ng/ml) was used. Mean values from triplicate experiments performed four times are depicted ± SEM. *p < 0.05 was considered significant. Exemplary
plots for the PPARα agonist WY14643 and the PPARδ agonist GW601514 are depicted. b Representative western blot analyses of endothelial cells that were
left untreated (solvent only) or were treated with WY14643 and L-165041 for 24 h at different concentrations. Comparable results were obtained from three
independent experiments. The results were normalized to the expression of tubulin. The relative expression of ICAM-1 is presented in % of control. The
mean values from three independent experiments are presented as the mean ± SEM. *p < 0.05. c Representative western blot analyses of endothelial cells
that were left untreated (solvent only) or were treated with WY14643 (200 μM) and L-165041 (50 μM) at different time points. Comparable results were
obtained from three independent experiments. The results were normalized to the expression of tubulin. The relative expression of ICAM-1 is presented in
% of control. The mean values from three independent experiments are presented as the mean ± SEM. *p < 0.05. d Adhesion assay for the functional
interaction between T cells (Jurkat) and endothelial cells: HUVECs were left untreated (solvent only) or were treated with PPARδ agonists for 24 h
(L-165041 (50 μM) and GW501514 (20 μM)) or (e) PPARα agonists for 24 h (Fenofibrat (100 μM) and WY14643 (200 μM)). As positive control TNFα (20 ng/
ml) was used. Jurkat cells were allowed to adhere to the endothelial cells for 3 min following stepwise increase of shear stress. The number of adherent
cells was quantified. The mean values from five independent experiments are presented as the mean ± SEM. *p < 0.05 was considered significant
Fig. 2 Effects of PPARα and δ agonists on the ICAM-1 mRNA expression. RT-PCR analyses of total mRNA extracted from HUVECs that were treated
with vehicle (solvent only) or L165041 and WY14643 for varying concentration as indicated for 24 h. Results were confirmed in three independent
sets of experiments. The results were normalized to the expression of GAPDH. The relative expression of ICAM-1 is presented in % of control.
The mean values from four independent experiments are presented as the mean ± SEM. *p < 0.05
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to activate transcriptional activity of the ICAM-1 pro-
moter (Fig. 3a). To further analyze the underlying mecha-
nisms of PPARδ agonist induced ICAM-1 promoter activity
a series of ICAM-1 promoter deletions was introduced into
a luciferase reporter construct and transiently transfected
into HUVECs (Fig. 3b). Interestingly, the deletion of a Sp1-
binding site located between −59/ −53 bp led to a complete
loss of PPARδ agonist induced ICAM-1 promoter activity.
In contrast, constructs containing this site demonstrated a
significant induction of ICAM-1 promoter acitivity during
PPARδ agonist treatment. Therefore, this single Sp1 site
seems to be responsible for PPARδ agonist conveyed
ICAM-1 promoter activity.
PPARδ agonists induce SP1 and Sp3 transcription factor
binding to the Sp1 binding site at −59/−53 bp
To determine the nuclear factor binding to the Sp1 bind-
ing site we performed EMSAs using nuclear extracts from
control and PPARδ agonist treated HUVEC, a wildtype
Sp1-oligonucleotide, a mutated Sp1-oligonucleotide and a
consensus Sp1 oligonucleotide (Fig. 3c). Here we could
demonstrate that the treatment with PPARδ agonists in-
duces transcription factor (TF) binding to the Sp1 binding
site. Via supershift analysis we could show, that not only
Sp1 but also Sp3 TFs bind to the wildtype ICAM-1 Sp-1
binding site between −59/−53 bp. A mutation of the Sp1





Fig. 3 Effects of PPARα and δ agonists on the ICAM-1 promoter activity and mRNA half-life. a Analyses of wildtype ICAM-1 luciferase (Luc) reporter
construct in HUVECs. The Luc activity is expressed in percent of control (mean ± SEM of three independent experiments each performed in triplicate).
HUVECs were left untreated (solvent only) or were treated with different concentrations of PPARα agonsist (WY14643 (200 μM) and PPARδ agonists
(L-165041 (50 μM)) for 24 h. As positive control TNFα (20 ng/ml) was used. Mean values from triplicate experiments with four independent experiments
are depicted ± SEM. *p < 0.05 was considered significant. b Analyses of 5′-deletional ICAM-1 promoter-based luciferase constructs in HUVECs. Schematic
representation of the respective reporter gene constructs on the left and the relative Luc activities (expressed as % activity of the control cells) in
graphic format on the right. HUVECs were left untreated (solvent only) or were treated with the PPARδ agonists (L-165041 (50 μM)) for 24 h. Results
were confirmed in four independent sets of experiments. *p < 0.05. c Representative EMSAs using nuclear extracts of HUVECs that were left untreated
(solvent only) or were treated with PPARδ agonists L-165041 (50 μM) for 24 h (lane 1,2): mutated labelled Sp1 DNA (lane 3), competition with
unlabelled wild-type DNA (lane 4, at 100 molar excess) or with unlabelled excess double-stranded Sp1 consensus oligonucleotides (lane 6, at a final
concentration of 0.35 lmol ⁄ l). Supershift analyses were performed by addition of specific Sp1 (lane 7 and 8) or Sp3 antibody (lanes 9 and 10, all from
Santa Cruz)) at a final concentration of 100 ng ⁄ ml. Formation of Sp-dependent binding complexes is indicated by arrows to the left. A representative
autoradiography from three independent experiments is shown. d HUVEC were incubated with vehicle, L165041 (50 μM) or WY14643 (200 μM) for 1 h,
followed by incubation with fresh media containing Act D (10 μg/ml) for 0, 12, 24 and 36 h. RT-PCR analyses for ICAM-1/GAPDH of total RNA extracted
from subconfluent cell cultures were performed. The PCR products were separated by 2 % agarose gel electrophoresis, and ethidium bromide stained
bands visualized using an ultraviolet transilluminator. ICAM-1 bands were quantified by densitometric scanning, the results of which were normalized
to amounts of GAPDH mRNA. The mean values from five independent experiments are presented as the mean ± SEM. *p < 0.05
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PPARα and PPARδ agonists induce ICAM-1 mRNA stability
ICAM-1 expression is not only controlled on the
transcriptional level, but can also be influenced by
mRNA stability. We therefore used actinomycin-D, a
transcription inhibitor, to determine whether PPARα or
δ agonists treatment increased ICAM-1 mRNA stability
in HUVECs. We found that ICAM-1 mRNA stability
was significantly increased in PPARα as well as PPARδ
agonist treated cells (Fig. 3d).
Discussion
Insights into the function of PPAR activators have
rapidly grown over the past decade. Recently, the impact
of PPAR agonists especially in endothelial cell function
and angiogenesis has been addressed [27–31]. These
findings are critical for uncovering the breadth of PPAR
functions in multiple cellular processes as PPAR agonists
become increasingly more prevalent in clinical practice.
Important pro-inflammatory cytokines, such as TNFα,
IL-1β, and LPS, are known to induce ICAM-1 expres-
sion, and PPAR agonists are capable of potently
suppressing these inflammatory effects [32–35]. There-
fore, PPAR agonists are promising anti-inflammatory
compounds for conditions such as chronic inflammatory
diseases, cancer or obesity. However, the effects of PPAR
activation in a non-inflammatory setting have not been pre-
viously addressed. This is an important consideration as
PPAR agonists enter clinical testing for treatment and pre-
ventative strategies in various non-inflammatory diseases.
In the current study, we demonstrated that PPARα
and PPARδ agonists effectively induced ICAM-1 expres-
sion in non-stimulated, quiescent endothelial cells. We
identified two mechanisms underlying this effect: a tran-
scriptional promoter-based mechanism for PPARδ ago-
nists via increased binding of the TF Sp1/Sp3 at the
ICAM-1 promoter between −59/53 bp and a posttran-
scriptional mechanism mediated by increased mRNA
stability for PPARα and PPARδ agonists. In addition, we
could demonstrate, that the increase in ICAM-1 surface
expression leads to an increased T-cell adherence in
PPARδ treated cells. Therefore, the current work
supports the possibility of a dual function of the PPARα
and δ agonists in endothelial cells that is dependent on
the activation status of the cell. This novel information
may have important implications for the responsiveness
of different disease types to treatment with these
compounds. The dual action of PPAR agonists may also
account for the variable effects of PPAR activation in the
treatment and development of distinct tumor entities
[36–38]. It is possible that the activation status of the
cancer cells or tumor stromal cells, including macro-
phages, fibroblasts, endothelial cells, and others, may
influence PPAR function.
Concerning adipocytes and endothelial cells such a
dual mechanism has been already described. Rodriguez-
Calvo et al. demonstrated a reduced IL-6 expression
after the previously LPS-stimulated adipocytes were
treated with the PPARδ activator GW501516 [39]. The
same group also showed an increase of IL-6 mRNA and
protein in the control group treated only with the
PPARδ agonist. Chen et al. demonstrated, that PPARγ
agonists significantly induce ICAM-1 expression in non
stimulated human vascular endothelial cells [19]. In
addition, it could be demonstrated that PPARδ agonists
induce IL-6 and IL-8 expression in non-stimulated
human endothelial cells [20]. On the other hand
Piqueras et al. demonstrated in TNFα stimulated
endothelial cells a suppression of the induced ICAM-1
expression via PPARδ agonist treatment [18].
Our results further demonstrated that PPARα and
PPARδ agonists influences ICAM-1 mRNA stability. The
regulation of ICAM-1 mRNA stability is a well-accepted
and important mechanism underlying posttranscrip-
tional control of ICAM-1 gene expression [40, 41].
PPARα agonists have already been implicated in regulat-
ing mRNA stability of other genes. Ren et al. demon-
strated that activation of PPARα resulted in reduced
nephrin mRNA stability, and therefore a decrease in
nephrin expression in kidney epithelial cells [42]. Meiss-
ner et al. showed that IL-8 mRNA stability was increased
by PPARδ agonist treatment [20]. These results demon-
strate the various, and likely context-dependent, mecha-
nisms by which PPAR agonists regulate gene expression.
Besides mRNA stability, we could demonstrate that
PPARδ agonists induce promoter activity via increased
binding of the TFs Sp1/Sp3 at the Sp1 binding site in
the proximal ICAM-1 promoter. Sp1 is one of the
important transcription factors of ICAM-1 expression in
endothelial cells. Brendji-Grün et al., demonstrated in
murine aortic endothelial cells that IL-1β induces ICAM-1
experession via critical Sp1 binding sites [43]. Kornschnabl
et al. showed that the Sp1 site between −59 and −53 bp is
essential for the ICAM-1 induction in cytomegalovirus
infected HUVEC [44]. Furthermore, Zhang et al recently
demonstrated that melanoma CD44 engagement wit
endothelial E-selectin leads to the induction of ICAM-1 via
increased binding of the TF Sp1 on the ICAM-promoter
[45]. Therefore, Sp1 is an important TF for ICAM-1 regula-
tion. We could demonstrate that the binding of Sp1/Sp3 on
the Sp1 site is essential for PPARδ induced ICAM-1
transcriptional expression. Recently, Okazaki et al., demon-
strated that PPARδ agonists increase human SIRT-1
transcription via increased Sp1 promoter binding [46].
Comparable results were demonstrated from Bonofiglio et
al., who showed that rosiglitazone, a PPARγ agonist, in-
duces fas ligand promoter activity via an increased Sp1 pro-
moter binding [47]. Hong et al. demonstrated a comparable
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mechanism of PPARγ dependent p21 increase via Sp1
dependent p21 promoter activity [48].
Interestingly, only the induction of ICAM-1 expression
by PPARδ agonists increased T-cell adhesion. PPARα
agonists failed to increase T-cell adherence. This might be
explained by the influence of PPARα agonists on the
expression of further adhesion molecules overriding the
effect of ICAM-1. Nevertheless, the induction of ICAM-1
by PPARα agonists might be relevant in a multi-drug
setting. It could be demonstrated that besides the facilitat-
ing of leukocyte trans-endothelial migration ICAM-1 can
for example bind fibrinogen preventing endothelial cell
apoptosis and influencing vasomotorical reactions [49].
Conclusion
Taken together, we have shown that treatment with PPARδ
agonists results in transcriptional and posttranscriptional
and the use of PPARα agonists in posttranscriptional induc-
tion of ICAM-1 expression in non-stimulated, quiescent
human endothelial cells. Furthermore, the effects of PPAR
agonists may depend on the activation status of endothelial
cells, and this status may dictate pro-inflammatory versus
anti-inflammatory responses. Therefore, these findings may
influence the future development and application of PPAR
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